Biogen, Samsung Humira copy wins EU approval

Fierce Pharma ------- The forces of competition are mounting against Humira in Europe with approval of a second biosimilar of the world’s best-selling drug at $16 billion in global sales. The European Commission Thursday gave its approval to Imraldi, which was developed by Samsung Bioepis, the joint venture between Biogen and South Korea’s Samsung Biologics. In March, the EU gave a green light to Amgen’s Amjevita, which has also been approved in the U.S. Imraldi was approved for all of the available indications, including rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, Crohn’s disease and ulcerative colitis and uveitis. To learn more click on the picture below to read the article.